Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Children
NCT03698279Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2018
- Primary completion
- Oct 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of Efluelda in influenza (6 arms), sponsored by Sanofi. Primary endpoints: Number of Participants With Immediate Unsolicited Adverse Events After Any Vaccination at 30 minutes, Number of Participants With Unsolicited Adverse Events After Any Vaccination at 28 days and 11 more. Started Oct 2018; status: completed.
02
Drugs
Efluelda
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03698279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03698279.